Wheeler Lab Members Publications Posters Directions
Posters
1. Cripe TP, Holub AD, Saini A, DeGregori J, Bergelson JM, Wheeler DL, and Dunphy EJ. Lack of the adenovirus major attachment receptor limits oncolysis of human rhabdomyosarcoma cells by adenovirus. Proc. Am. Assoc. Cancer Res. 41: 2879, San Francisco, CA, 2000.
2. Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, and Verma AK. Protein kinase C epsilon transgenic mice: A unique model for metastatic squamous cell carcinoma. Proc. Am. Assoc. Cancer Res. 42: 4919, New Orleans, LA, 2001.
3. Wheeler DL and Verma AK. intron/exon structure and genetic polymorphism of the murine protein kinase Delta gene. Proc. Am. Assoc. Cancer Res. 42: 4012, 2001.
4. Wheeler DL, Dreckschmidt NE, Hayes KL, Oberley TD, Ananthaswamy HN, and Verma AK, Inhibition of metastatic squamous cell carcinoma development by a-Difluoromethylornithine accompanied by a marked regression of hair follicle growth and alopecia in protein kinase C epsilon transgenic mice. Proc. Am. Assoc. Cancer Res. 43: 5014, San Francisco, CA, 2002.
5. Wheeler DL, Reddig PJ, Dreckschmidt NE, Leitges M and Verma AK. Protein kinase Cδ-mediated signal to ornithine decarboxylase induction is independent of skin tumor suppression. Proc. Am. Assoc. Cancer Res. 43: 5013, San Francisco, CA, 2002.
6. Wheeler DL, Ness KJ, Dreckschmidt NE, Oberley TD and AK Verma. The role of proinflammatory cytokine TNFα in PKCε signaling network in the development of metastatic squamous cell carcinomas. 5th International Skin Carcinogenesis Meeting, Gifu, Japan, October 2002.
7. Wheeler DL, Ness KJ, Dreckschmidt NE, Oberley TD and Verma AK. Protein Kinase C epsilon (PKCε) transgenic mice: A unique model to investigate myeloproliferative like syndromes, a group of pre-hematopoietic neoplasms. AACR Mouse Models of Cancer Orlando, FL, 2003.
8. Li Y, Wheeler DL, Verma AK and Oberley TD. Inflammation plays and important role in distinguishing the distinct mechanisms of Protein Kinase Cδ and Protein Kinase Cε mediate response to 12-0-tetradecanoylphorbol-13-acetate. Society for Investigative Dermatology, 65th Annual Meeting, Miami Beach, FL, 2003.
9. Wheeler DL, Ness KJ, Dreckschmidt NE, Oberley TD and Verma AK. TPA-stimulated serum Tumor Necrosis Factor α (TNFα) levels in PKCε transgenic mice: Possible link with PKCε-mediated increased Tumor Necrosis Factor Converting Enzyme (TACE) activity and development of metastatic squamous cell carcinoma. Proc. Am. Assoc. Cancer Res. 44: 3015, Washington, DC 2003.
10. Wheeler DL, Ness KJ, Dreckschmidt NE, Oberley TD and Verma AK. Protein Kinase C epsilon (PKCε) transgenic mice: A unique model to investigate myeloproliferative diseases. Proc. Am. Assoc. Cancer Res. Washington, DC, Late-Breaking Abstract, 2003.
11. Verma AK, Ananthaswamy HN, Matsumura Y and Wheeler DL. Protein Kinase C epsilon is an endogenous photosensitizer in FVB/N mice that enhances UVB radiation-induced tumor necrosis factor alpha release, p53 expression, ornithine decarboxylase activity, the events preceding photocarcinogenesis, American Society of Photobiology, Baltimore, MD, 2003.
12. Wheeler DL and Verma AK. Development of metastatic squamous cell carcinomas in PKCε transgenic mice is possibly mediated by pro-inflammatory cytokines in a paracrine mechanism. Proc. Am. Assoc. Cancer Res. Orlando, FL, 2004, Awarded AACR Scholar-in-Training Award.
13. Wheeler DL, Ness KJ, Martin KE, Dreckschmidt NE, Ananthaswamy HN, Mitchell DL, and Verma AK. Protein Kinase C Epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas. 14th Int Congress on Photobiology Jeju, Korea, June 2004.
14. Wheeler DL and Verma AK. Tumor necrosis factorα, a pro-inflammatory cytokine, is linked to the susceptibility of protein kinase Cε transgenic mice to ultraviolet radiation--induced cutaneous damage and development of squamous cell carcinoma. Am. Soc. Photobiol., Seattle WA, July 2004.
15. Verma AK, Wheeler DL, Ness KJ, and Martin KE. Protein kinase C δ is not a tumor suppressor in ultraviolet light-induced mouse skin carcinogenesis. Am. Assoc. Cancer Res. Anaheim, CA, 2005.
16. Li Y, Wheeler DL, Alter W, Chaiswing L, Ananthaswamy HN, Verma AK, and Oberley TD. Analysis of Early Morphologic Changes and Cytokine Levels in Mouse Skin Following a Single 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate Treatment: the Effect of Constitutive overexpression of PKCe. Am. Assoc. Cancer Res. Anaheim, CA, 2005.
17. Wheeler DL, Anderson TA, and Rohrschneider LR. The sSHIP promoter is expressed in the bulge region during anagen of the hair follicle cycle. Fred Hutchinson Cancer Research Center, Basic Science Division, Annual Retreat, Semiahmoo, WA, 2005.
18. Wheeler DL, Anderson TA, and Rohrschneider LR. The sSHIP promoter is expressed during differentiation and proliferation phases of the mouse epidermis, Timberline Symposium on Epithelial Cell Biology, Timberline, OR, 2006.
19. Aziz MH, Wheeler DL, Bhamb B, and Verma AK. PKC ε, but not PKC δ overexpression, alters susceptibility to ultra-violet induced development of squamous cell carcinomas, AM. Assoc. Cancer Res. Washington DC, 2006.
20. Wheeler DL, Kruser TJ, Huang S, Gondi V, Armstrong EA and Harari PM. Development and characterization of EGFR inhibitor resistant lines; A model to study acquired resistance to EGFR blockade, Molecular Diagnostics in Cancer Therapeutic Development, Chicago, IL, 2006.
21. Kruser TJ, Wheeler DL, Huang S, Armstrong EA, Sliwkowski M, Hicklin D and Harari PM. Dual Agent Targeting of EGFR and ErbB2 with Cetuximab and 2C4: A Strategy to Overcome Acquired Resistance, 2007 Multidisciplinary Head and Neck Cancer Symposium, Palm Springs, 2007.
22. Wheeler DL, Kruser TJ, Nechrebecki MM, Huang S, and Harari PM. Acquired Resistance to Cetuximab; Rationale for Sequential Therapies Targeting the EGFR, Molecular Targets of Cancer; Keystone Symposia, Whistler, British Columbia, NCI Scholar Award, 2007.
23. Huang S, Wheeler DL, Cannon M and Harari PM. Alterations in EGFR trafficking and degradation in EGFR-inhibitor resistant tumor cells, Proc. Am. Assoc. Cancer Res., 48:1258, Los Angeles, CA, 2007.
24. Wheeler DL, Ghia AJ, Kruser TJ, Armstrong EA, Nechrebecki MM, Huang S, and Harari PM. Role of Src family kinases in acquired resistance to cetuximab, Molecular Targets and Cancer Therapeutics, AACR, San Francisco, CA, AACR-Travel Award, 2007.
25. Kruser TJ, Wheeler DL, Huang S, Armstrong EA, Coxon A, Starnes C, Polverino T, Radinsky R and Harari PM. Modulation of radiation response by motesanib diphosphate in models of head and neck squamous cell carcinoma, Am. Assoc. Cancer Res. San Diego, CA, 2008.
26. Nyflot M, Grudzinski J, Titz B, Armstrong E, Wheeler DL, Harari PM, and Jeraj R. [18F]FLT PET imaging to assess proliferative response to an EGFR inhibitor in murine tumor models, AAPM, 2008.
27. Li, C, Iida, M, Dunn, E, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab, Molecular Targets of Cancer; Keystone Symposia, Whistler, British Columbia, 2009.
28. Huang, S, Li, C, Armstrong, EA, Wheeler, DL, Harari, PM. Modulation of acquired resistance to cetuximab and radiation by p53. Am. Assoc. Cancer Res. Denver, CO, 2009
29. Sand, JM, Aziz, MH, Wheeler, DL, Dreckschmidt, NE, Verma, AK. Ultraviolet radiation-induced development of squamous cell carcinomas in protein kinase Ce transgenic mice accompanies TNFa release and proliferation of hair follicle putative stem cells, Am. Assoc. Cancer Res. Denver, CO, 2009
30. Clark, PA, Iida, M, Wheeler, DL, Kuo, JS. Compensatory activation of EGFR family member receptors in glioblastoma cancer stem cells may mediate resistance to anti-EGF therapies, Am. Assoc. Cancer Res. Denver, CO, 2009
31. Hatakeyama, H, Parker, J, Wheeler, DL, Harari, PM, Levy, S and Chung, CH, Insulin-like Growth Factor-I Receptor Inhibitor Sensitizes Head and Neck Cancer Cells to Cetuximab and Methotrexate, ASCO, Orlando, FL, 2009
32. Harari, PM, Huang, S, and Wheeler, DL. Clinical resistance to EGFR inhibitors, ICTR, Geneva, Switzerland, 2009
33. Myers, R, Dunn, EF and Wheeler, DL. OSI-906 as an Effective Therapy in Insulin-like Growth Factor Receptor 1 Expressing Squamous Cell Carcinoma of the Head and Neck, Undergraduate Research Symposia Madison, WI, 2009
34. Neuman, E, Dunn, EF and Wheeler, DL. Preclinical Evaluation of Dasatinib in Colorectal Cancer with Intrinsic Resistance to Cetuximab, Undergraduate Research Symposia Madison, WI, 2009
35. Stegman, H, Kanders, J.H.A.M, Wheeler, DL, Span, PN, van der Kogel, AJ, Bussink, J. Biological tumor characteristics and repair modulation of radiation-induced DNA damage by EGFR inhibition, 11th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology, Wolfsberg Castle, Ermatingen, Switzerland, June 27-29, 2009
36. Dunn, EF, Iida, M, Myers, R, Armstrong, EA, Li, C, Wheeler, DL, Dasatinib resensitizes Kras mutant colorectal lines to cetuximab, Molecular Targets and Cancer Therapeutics, AACR, Boston, MA, 2009.